NJ State Employees Deferred Compensation Plan’s Royalty Pharma RPRX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,000	Closed	-$847K	–	328
2025 Q3	$847K	Hold	24,000	–	–	0.09%	209
2025 Q2	$865K	Hold	24,000	–	–	0.1%	194
2025 Q1	$747K	Hold	24,000	–	–	0.1%	200
2024 Q4	$612K	Hold	24,000	–	–	0.07%	251
2024 Q3	$679K	Hold	24,000	–	–	0.08%	238
2024 Q2	$633K	Hold	24,000	–	–	0.08%	237
2024 Q1	$729K	Hold	24,000	–	–	0.09%	222
2023 Q4	$674K	Buy	+24,000	New	+$660K	0.09%	228

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's RPRX Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 24,000 shares — an estimated $847K sold.

NJ State Employees Deferred Compensation Plan first reported a position in RPRX in Q4 2023 and held it in 8 quarters. The position peaked at $865K in Q2 2025. 538 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 24,000 Royalty Pharma shares in Q4 2025, an estimated $847K.
NJ State Employees Deferred Compensation Plan first reported a position in Royalty Pharma in Q4 2023 and held it in 8 quarters.
NJ State Employees Deferred Compensation Plan's Royalty Pharma position peaked at $865K in Q2 2025.
538 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.